{"id":"W2264000214","doi":"10.1016/s1470-2045(15)00551-3","title":"Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":565,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"Puma Biotechnology","keywords":"Neratinib; Medicine; Trastuzumab; Internal medicine; Breast cancer; Oncology; Placebo; Regimen; Cancer; Metastatic breast cancer; Adjuvant therapy; Gynecology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001490894,0.0003979465,0.001664091,0.0001802675,0.0000987517,0.00003377311,0.0003357736,0.0002344221,0.00172162],"category_scores_gemma":[0.0001066338,0.0001801955,0.0001836916,0.000253747,0.0004136075,0.00009667927,0.00004490789,0.0005783624,0.00005661805],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001028845,"about_ca_system_score_gemma":0.001560501,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004751995,"about_ca_topic_score_gemma":0.00158679,"domain_scores_codex":[0.9959418,0.001144232,0.0006656729,0.0005934307,0.0006737791,0.0009810483],"domain_scores_gemma":[0.9971665,0.001296955,0.0002734593,0.0006428206,0.000365243,0.0002550828],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9058359,0.002886599,0.01337773,0.00002556816,0.0003486877,0.00013165,0.0006484192,0.00002558789,0.0002885623,0.000006289471,0.0008952784,0.07552978],"study_design_scores_gemma":[0.9682581,0.008802828,0.01816102,0.0003324388,0.0001637703,0.00001329573,0.00004766642,0.0002232548,0.0004828948,0.000007250906,0.003252485,0.0002549246],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9699923,0.0004161376,0.00009621986,0.01531507,0.0004139863,0.01258752,0.0002594172,0.0000558643,0.0008634477],"genre_scores_gemma":[0.9871892,0.0003159998,0.0001331119,0.002805911,0.001467549,0.007566513,0.00003299761,0.00007094114,0.0004177709],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07527485,"threshold_uncertainty_score":0.9991909,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04734896813518842,"score_gpt":0.3900358492526455,"score_spread":0.3426868811174571,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}